Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of RXC004 as
monotherapy and in combination with Nivolumab in patients with advanced malignancies. In
order to define the doses and schedules for further clinical evaluation.